Medtronic Reports Strong Q4 and Full-Year Fiscal Results
Medtronic reported strong fiscal fourth-quarter and full-year revenue, exceeding expectations with growth driven by cardiac ablation, diabetes, medical-surgical products, and neuroscience platforms. The company expects continued outgrowth in fiscal 2027 despite a $250 million tariff impact.
Tickers: $MDT
Topics: cardiac_ablation diabetes_care medical_devices revenue_growth